Company intelligence / Profile preview

Auxesis Pharma

Los Angeles, California, United States

Ownership: Private
Development stage: Other

Overview

Auxesis Pharma is a clinical-stage specialty pharmaceutical company focused on developing innovative topical therapies for rare and severe pain disorders. The company's lead candidate, AUX-001, is being developed for the treatment of erythromelalgia, a rare neurovascular condition characterized by episodes of burning pain, redness, and swelling. By utilizing a proprietary topical delivery system, Auxesis aims to provide localized relief with minimal systemic side effects. The company is also exploring applications for its technology in other neuropathic pain indications.

Therapeutic areas: CardiovascularNeurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

asacaine

Unknown

Partnerships

Yale University

Beyond the preview

Go deeper on Auxesis Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Auxesis Pharma.

Explore the full profile